BioMarin Pharmaceutical
BMRN
$54.89
-0.56%
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases, with a portfolio of eight approved products spanning enzyme replacement therapies, gene therapies, and treatments for conditions such as achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. The company is a leader in the rare disease space, distinguished by its specialized focus on underserved genetic disorders and its expanding pipeline of early-stage programs in skeletal conditions and enzyme therapies. The current investor narrative centers on the commercial trajectory of Voxzogo (vosoritide) for achondroplasia and its recent Phase 3 success in hypochondroplasia, which opens a significant new market opportunity, as well as the company's strategic royalty deal with Ascendis Pharma that converts a competitive threat into a royalty-bearing asset. However, debates persist around potential market share erosion from emerging oral competitors and the sustainability of growth as the company navigates a competitive landscape.…
BMRN
BioMarin Pharmaceutical
$54.89
Related headlines
Investment Opinion: Should I buy BMRN Today?
Based on the synthesis of analyst consensus, valuation metrics, and growth prospects, BioMarin receives a Buy rating with a caveat for risk-tolerant investors. The core thesis is that the market is significantly undervaluing BioMarin's earnings potential, as evidenced by the forward PE of 8.64x versus the trailing PE of 32.65x, and the analyst average target of $91.62 implies 60.2% upside. The recent Phase 3 success in hypochondroplasia provides a clear catalyst for revenue acceleration, and the royalty deal with Ascendis Pharma demonstrates strategic acumen in mitigating competitive threats.
The supporting evidence is compelling: revenue grew 19.91% year-over-year in Q2 2026 to $989.7 million, driven entirely by product sales; gross margin remains high at 79.51%; free cash flow is robust at $732.9 million on a trailing basis; and the balance sheet is fortress-like with a current ratio of 5.21 and debt-to-equity of 0.106. The price-to-sales ratio of 3.54x is moderate for the biotechnology sector, and the price-to-book ratio of 1.87x is below the industry average, suggesting the market is not overly exuberant about the company's assets. The consensus recommendation of 1.74 (Buy) from 26 analysts reinforces the positive outlook.
However, several risks could invalidate this thesis. First, the forward PE of 8.64x relies on estimated EPS of $9.57, which is a dramatic increase from the trailing EPS of $0.03; any shortfall in earnings could trigger a sharp re-rating. Second, competitive threats from BridgeBio and oral rivals could erode Voxzogo's market share and pricing power. Third, the stock's persistent underperformance relative to the S&P 500 (-12.1% relative strength over 1 year) suggests that the market is not yet convinced of the growth story. The rating would upgrade to a Strong Buy if Q3 2026 earnings show EPS exceeding $1.50 and revenue growth above 20%, or downgrade to Hold if revenue growth decelerates below 10% or if gross margins fall below 75%. Relative to its history and peers, BioMarin appears undervalued on a forward earnings basis, but fairly valued on a trailing basis, making it a compelling GARP (Growth at a Reasonable Price) candidate.
Sign up to view all
BMRN 12-Month Price Forecast
BioMarin presents a classic value-versus-growth dilemma: the forward PE of 8.64x suggests deep undervaluation, but the trailing EPS of $0.03 and recent quarterly losses highlight the fragility of the earnings recovery. The bull case is supported by a robust pipeline, a strategic royalty deal, and overwhelming analyst optimism, while the bear case is anchored in competitive threats, margin compression, and persistent relative underperformance. The stock's low beta of 0.238 and high short ratio of 5.62 indicate that sentiment is polarized, with significant downside if upcoming catalysts disappoint. I would upgrade to bullish if Q3 2026 earnings show EPS above $1.50 and revenue growth exceeding 20%, and downgrade to bearish if Voxzogo sales decline sequentially or if BridgeBio announces an earlier-than-expected FDA approval.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BioMarin Pharmaceutical's 12-month outlook, with a consensus price target around $91.62 and implied upside of +66.9% versus the current price.
Average Target
$91.62
0 analysts
Implied Upside
+66.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$60 - $124
Analyst target range
The analyst community is overwhelmingly bullish on BioMarin, with 26 analysts covering the stock and a consensus recommendation of 'Buy' (mean rating of 1.74 on a scale where 1 is Strong Buy). The average target price is $91.62, which implies a substantial upside of approximately 60.2% from the current price of $57.18. This consensus reflects strong confidence in the company's pipeline and commercial prospects, particularly following the positive Phase 3 data for VOXZOGO in hypochondroplasia. The distribution of ratings is skewed towards buy equivalents, with recent actions from firms like Jefferies (Buy), Piper Sandler (Overweight), and Morgan Stanley (Overweight) reinforcing the positive sentiment.
Bulls vs Bears: BMRN Investment Factors
The bull case for BioMarin rests on a powerful combination of deep value (forward PE of 8.64x), overwhelming analyst optimism (60.2% upside to average target), and a pipeline catalyst in hypochondroplasia that could significantly expand the Voxzogo franchise. However, the bear case is equally compelling: the stock has severely underperformed the market (-12.1% relative strength over 1 year), earnings have been volatile with recent quarterly losses, and competitive threats from BridgeBio and oral rivals loom large. Currently, the bear evidence appears stronger on a near-term basis given the stock's price action and margin compression, but the bull case could quickly gain traction if Q3 2026 results show sustained revenue acceleration and margin stabilization. The single most important tension is whether the forward PE of 8.64x is a value trap or a genuine opportunity—this hinges entirely on whether BioMarin can deliver the estimated EPS of $9.57, which would require a dramatic profitability improvement from the current trailing EPS of $0.03.
Bullish
- Analyst Consensus Strong Buy with 60% Upside: 26 analysts covering BMRN have a consensus recommendation of 'Buy' (mean rating 1.74), with an average target price of $91.62, implying 60.2% upside from the current $57.18. The low target of $60 still offers 4.9% upside, while the high target of $124 implies 116.9% upside, indicating broad-based optimism.
- Forward PE of 8.64x Signals Deep Value: While the trailing PE is 32.65x, the forward PE drops to 8.64x based on estimated EPS of $9.57, suggesting the market is pricing in a massive earnings inflection. This gap implies analysts expect net income to more than triple, driven by Voxzogo's expansion into hypochondroplasia and operating leverage.
- Voxzogo Hypochondroplasia Phase 3 Success: The positive Phase 3 trial for VOXZOGO in hypochondroplasia opens a new market potentially doubling the addressable patient population beyond achondroplasia. This catalyst drove a sharp stock rally in May 2026, with shares jumping from ~$50 to over $70 within three months.
- Royalty Deal Neutralizes Competitive Threat: BioMarin's royalty agreement with Ascendis Pharma converts a potential competitor into a royalty-bearing asset, providing a recurring revenue stream that offsets some market share erosion risk. This strategic move demonstrates management's ability to protect shareholder value amid rising competition.
Bearish
- Severe Relative Underperformance vs. S&P 500: BMRN has underperformed the S&P 500 by 12.1% over the past year and 16.7% year-to-date, with a 1-year price change of just +2.90% versus SPY's +15.01%. This persistent weakness suggests structural issues or waning investor confidence despite the bullish analyst narrative.
- Earnings Volatility with Recent Quarterly Losses: BioMarin reported net losses in Q3 2025 (-$30.7M) and Q4 2025 (-$46.6M), with EPS of -$0.16 and -$0.24 respectively. This earnings instability raises questions about the sustainability of the forward PE of 8.64x, which relies on a sharp profitability rebound.
- Gross Margin Compression in Q2 2026: Gross margin declined to 79.51% in Q2 2026 from 81.82% in Q2 2025, and further from 81.95% in Q3 2025. This 231 basis point year-over-year contraction, if sustained, could pressure operating margins and delay the earnings inflection needed to justify the forward valuation.
- Competitive Threats from BridgeBio and Oral Rivals: BridgeBio's successful Phase 3 trial for its achondroplasia treatment and planned FDA filing in 2026 pose a direct threat to Voxzogo's market share. Additionally, emerging oral competitors could disrupt the injectable market, potentially eroding BioMarin's pricing power and revenue growth.
BMRN Technical Analysis
BioMarin's stock has been in a recovery phase over the past year, with a 1-year price change of +2.90%, though it remains well below its 52-week high of $70.98. The current price of $57.18 sits at approximately 33% of the 52-week range (calculated as ($57.18 - $49.26) / ($70.98 - $49.26)), indicating that the stock is in the lower half of its annual range despite the positive yearly return. This positioning suggests that while the stock has recovered from its lows, it has not yet reclaimed the momentum seen earlier in the year, leaving room for either a continuation of the uptrend or a retest of support. The 52-week low of $49.26 provides a critical floor, and the stock's current level reflects a market that is cautiously optimistic but not fully convinced of a sustained breakout.
Beta
0.21
0.21x market volatility
Max Drawdown
-22.5%
Largest decline past year
52-Week Range
$49-$71
Price range past year
Annual Return
+0.4%
Cumulative gain past year
| Period | BMRN Return | S&P 500 |
|---|---|---|
| 1m | -15.1% | +1.0% |
| 3m | -7.2% | +2.5% |
| 6m | +0.7% | +13.9% |
| 1y | +0.4% | +15.0% |
| ytd | -7.7% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BMRN Fundamental Analysis
BioMarin's revenue trajectory has been volatile but shows signs of stabilization, with the most recent quarter (Q2 2026) reporting revenue of $989.7 million, a 19.91% year-over-year increase from $825.4 million in Q2 2025. This growth was driven entirely by product sales, which accounted for $984.4 million, while royalty and other revenue contributed just $5.3 million. However, the multi-quarter trend reveals inconsistency: Q1 2026 revenue was $766.2 million, down from $745.1 million in Q1 2025, and Q4 2025 revenue of $874.6 million was higher than Q4 2024's $747.3 million, indicating that growth is not linear and may be influenced by seasonal or one-time factors. The strong Q2 2026 performance, coupled with the recent Phase 3 success in hypochondroplasia, suggests that the company's growth story is intact, but investors should monitor whether this acceleration can be sustained.
Quarterly Revenue
$989708000.0B
2026-06
Revenue YoY Growth
+19.9%
YoY Comparison
Gross Margin
79.5%
Latest Quarter
Free Cash Flow
$732878000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BMRN Overvalued?
Given that BioMarin reported positive net income of $44.8 million in the most recent quarter (Q2 2026), the PE ratio is the appropriate primary valuation metric. The trailing PE stands at 32.65x, while the forward PE is significantly lower at 8.64x, implying that the market expects substantial earnings growth in the coming year. This large gap between trailing and forward multiples suggests that analysts are forecasting a sharp increase in profitability, likely driven by new product launches and margin expansion. Compared to the biotechnology industry average PE of approximately 20-25x, BioMarin's trailing PE of 32.65x represents a premium of roughly 30-60%, but the forward PE of 8.64x indicates a steep discount, reflecting high growth expectations. The stock's price-to-sales ratio of 3.54x is moderate for the sector, while the price-to-book ratio of 1.87x is below the industry average, suggesting that the market is not overly exuberant about the company's asset base.
PE
32.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~138x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.7x
Enterprise Value Multiple
Investment Risk Disclosure
BioMarin's financial risks are moderate but noteworthy. The company carries a debt-to-equity ratio of just 0.106, indicating low leverage, and a current ratio of 5.21 provides ample liquidity. However, the trailing PE of 32.65x is elevated relative to the biotechnology industry average of 20-25x, and the trailing EPS of $0.03 leaves little margin for error. The forward PE of 8.64x assumes a massive earnings jump to $9.57 per share, which is a high-risk projection given the company's recent quarterly losses (Q3 2025 EPS of -$0.16, Q4 2025 EPS of -$0.24). Additionally, gross margin compression to 79.51% in Q2 2026 from 81.82% a year earlier could signal pricing pressure or rising costs, threatening the profitability inflection needed to justify the forward valuation.
Market and competitive risks are significant. BioMarin's beta of 0.238 indicates low correlation with the broader market, which may appeal to risk-averse investors but also means the stock has not benefited from the recent market rally (SPY up 15.01% over 1 year vs. BMRN up 2.90%). The competitive landscape is intensifying: BridgeBio's successful Phase 3 trial for its achondroplasia treatment and planned FDA filing in 2026 directly threatens Voxzogo's market share, while emerging oral competitors could disrupt the injectable market. The recent royalty deal with Ascendis Pharma mitigates some risk but does not eliminate the threat of market share erosion. Furthermore, the stock's short ratio of 5.62 suggests that a significant portion of the market is betting against the company's growth story, which could lead to sharp downside if upcoming data disappoints.
The worst-case scenario for BioMarin would involve a combination of factors: Voxzogo sales miss expectations due to competitive pressure from BridgeBio, the hypochondroplasia launch underperforms, and the company fails to achieve the projected EPS of $9.57, causing the forward PE to revert to the trailing level. In this scenario, the stock could retest its 52-week low of $49.26, representing a 13.9% decline from the current price of $57.18. If the market re-rates the stock to a more conservative multiple, the downside could extend to the analyst low target of $60 (which is actually above the current price, suggesting limited downside based on analyst estimates) or even below if sentiment deteriorates further. The maximum drawdown over the past year was -22.49%, indicating that a decline of 20-25% from current levels is plausible in a severe adverse scenario, bringing the stock to the $43-46 range.
FAQ
The key risks for BMRN can be ranked by severity: first, competitive risk from BridgeBio's achondroplasia treatment, which has completed a successful Phase 3 trial and plans an FDA filing in 2026, potentially eroding Voxzogo's market share; second, financial risk stemming from earnings volatility, with recent quarterly losses (Q4 2025 net loss of $46.6 million) and a trailing EPS of just $0.03, making the forward PE of 8.64x highly dependent on optimistic estimates; third, operational risk from gross margin compression, which declined to 79.51% in Q2 2026 from 81.82% a year earlier, potentially signaling pricing pressure; and fourth, market risk given the stock's low beta of 0.238 and high short ratio of 5.62, which could amplify downside volatility if sentiment turns negative.
The 12-month forecast for BMRN includes three scenarios: a bull case with 30% probability targeting $91.62-$124.00, driven by successful hypochondroplasia launch and EPS exceeding $9.57; a base case with 50% probability targeting $70.00-$85.00, assuming steady revenue growth of 12-15% and gradual margin improvement; and a bear case with 20% probability targeting $49.26-$60.00, reflecting competitive pressures and failure to achieve earnings estimates. The base case is most likely, hinging on Voxzogo revenue growing 15-20% annually and gross margin stabilizing around 78-80%. The wide range of outcomes reflects the high uncertainty surrounding the company's earnings trajectory and competitive landscape.
BMRN appears undervalued on a forward basis but fairly valued on a trailing basis. The trailing PE of 32.65x is a premium to the biotechnology industry average of 20-25x, but the forward PE of 8.64x represents a steep discount, implying the market expects a massive earnings inflection. The price-to-sales ratio of 3.54x is moderate for the sector, and the price-to-book ratio of 1.87x is below the industry average, suggesting the market is not overly exuberant about the company's assets. The valuation implies that the market expects BioMarin to deliver on its estimated EPS of $9.57, a 312x increase from the trailing EPS of $0.03. If the company fails to meet these expectations, the stock could be overvalued at current levels.
From a risk/reward perspective, BMRN offers a compelling but high-risk opportunity. The analyst consensus target of $91.62 implies 60.2% upside, and the forward PE of 8.64x suggests the stock is undervalued if earnings estimates are met. However, the trailing EPS of $0.03 and recent quarterly losses (Q3 2025 EPS of -$0.16, Q4 2025 EPS of -$0.24) highlight the execution risk. The biggest downside risk is competitive pressure from BridgeBio, which could erode Voxzogo's market share and cause the stock to retest its 52-week low of $49.26, representing a 13.9% decline. For risk-tolerant investors with a 2-3 year horizon, BMRN is a good buy on dips, but conservative investors should wait for clearer evidence of sustainable profitability.
BMRN is best suited for long-term investment with a minimum holding period of 2-3 years, given its pipeline-driven growth story and the time required for Voxzogo's hypochondroplasia launch to materialize. The stock's low beta of 0.238 and lack of dividend (payout ratio 0%) make it less appealing for short-term trading or income generation. However, the high short ratio of 5.62 and recent volatility (max drawdown of -22.49% over the past year) suggest that short-term traders could exploit price swings around catalysts like earnings reports or FDA decisions. For long-term investors, the key is to monitor the company's ability to achieve the estimated EPS of $9.57 and sustain revenue growth above 15%, which would justify the forward valuation and drive significant upside.